Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib vs Imatinib in Newly Diagnosed CP CML (BFORE)
NCT02130557Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of bosutinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Pfizer. Primary endpoint: Major Molecular Response at 12 months. Started Jul 2014; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02130557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130557.